Viewing nowCombinationSitaphol M Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.

MFDS item code 202204572 · Approved 2022.12.21 · Insurance code 622804970
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood glucose control for patients with type 2 diabetes. When taken alongside dietary and exercise therapies, it effectively controls blood sugar levels to maintain a healthy glucose level. The combination of sitagliptin and metformin enhances the efficacy of lowering blood glucose. Therefore, it is suitable for patients with type 2 diabetes who need blood sugar management.
In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for patients who do not achieve adequate glycemic control with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this drug for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), provided they do not have other conditions that may increase the risk of lactic acidosis, by adjusting the dose as follows. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, which are used to help control blood sugar levels. Serious allergic reactions may occur while taking this medication; discontinue immediately and consult a physician if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear. There is a risk of acute pancreatitis, which is inflammation of the pancreas, so notify healthcare professionals immediately if symptoms such as abdominal pain, nausea, or vomiting occur. Patients with decreased kidney function, severe infections, dehydration, acute myocardial infarction, or heart failure should not take this medication. The medication should be temporarily discontinued before tests using iodine contrast agents, and usage should resume only after kidney function is confirmed to be normal post-examination. Women who are pregnant or may become pregnant, as well as nursing mothers, are advised not to take this medication. There is a risk of hypoglycemia with this medication; caution is especially needed when taken with other antidiabetic agents or insulin, and appropriate measures should be taken immediately if symptoms of hypoglycemia occur. The metformin component can rarely cause a serious metabolic disorder known as lactic acidosis, so immediate medical attention should be sought if sudden fatigue, muscle pain, difficulty breathing, or abdominal pain occur during treatment. Patients with impaired liver function or excessive alcohol consumption should exercise caution when using this medication due to increased risks. While taking this medication, regular blood tests and kidney function tests should be performed, and vitamin B12 levels should be monitored periodically. Patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume only after confirming that kidney function has returned to normal following the procedure. The safety and efficacy of this medication have not been established in children under 18 years of age and its use is not recommended. In elderly patients, kidney function may decline, so dose adjustments and regular kidney function monitoring are necessary. In case of overdose, immediate hospital treatment should be sought, and the sitagliptin component may be partially removed through hemodialysis. Alcohol consumption should be avoided while taking this medication, as the risk of lactic acidosis may be increased when taken with alcohol. This medication may interact with other drugs, so it is essential to inform healthcare providers of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture, and kept at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy over time.
Dark pink oval film-coated tablet
56 tablets/box[(14 tablets/PTP×4)], 200 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.